Combination of monosaccharides and adenosine and use thereof
AssigneeL'oreal
InventorsJulien LABOUREAU, Jean-Thierry Simonnet, Pascal Portes
Life of this patent
Estimating the term…
Abstract
The present invention relates to a composition, especially a cosmetic and/or dermatological composition, containing, in a physiologically acceptable medium, a combination of at least one monosaccharide chosen from mannose, rhamnose and a mixture thereof, and of at least one additional compound chosen from adenosine, an analogue thereof and a mixture thereof.
Claims14
A composition comprising, in a physiologically acceptable medium, at least one monosaccharide chosen from mannose and rhamnose and at least one additional compound chosen from adenosine and adenosine analogues, in which the amount of said at least one additional compound is between 0.01% and 10% by weight relative to the total weight of the composition,
- and in which the additional compound is chosen from adenosine, 2′-deoxyadenosine, 2′,3′-isopropylideneadenosine, toyocamycine, 1-methyladenosine, N-6-methyladenosine, adenosine N-oxide, 6-methylmercaptopurine riboside, 6-4 chloropurine riboside, phenylisopropyladenosine (PIA), 1-methylisoguanosine, N6-cyclohexyladenosine (CHA), N6-cyclopentyladenosine (CPA), 2-chloro-N6-cyclopentyladenosine, 2-chloroadenosine, N6-phenyladenosine, 2-phenylaminoadenosine, MECA, N6-phenethyladenosine, 2-p-(2-carboxyethyl)phenethylamino-5′-N-ethylcarboxamidoadenosine (CGS-21680), N-ethylcarboxamidoadenosine (NECA), 5′-(N-cyclopropyl)carboxamidoadenosine, DPMA (PD 129,944), metrifudil, erythro-9-(2-hydroxy-3-nonyl)adenine (EHNA), iodotubercidine, the compounds of formula (I):
- in which:
- R1 and R2, which are identical, denote a linear saturated C1-C6 or unsaturated C2-C6, or branched saturated or unsaturated C3-C6 hydrocarbon-based radical, or alternatively form, together with the oxygen atoms to which they are attached, an isopropylidene radical;
- R3 denotes:
- (i) a linear saturated C1-C10 or unsaturated C2-C10, or branched saturated or unsaturated C3-C10 hydrocarbon-based radical, optionally substituted with at least one group chosen from —OR′, —NR′R″, —COOR′, CONR′R″, —CF3, —F, —OCF3, —CN and —NO2, or
- (ii) a group —COR4 with R4 denoting a linear saturated C1-C9 or unsaturated C2-C9, or branched saturated or unsaturated C3-C9 hydrocarbon-based radical, optionally substituted with at least one group chosen from —OR′, —NR′R″, —COOR′, —CONR′R″, —CF3, —F, —OCF3, —CN and —NO2;
- or
- (iii) a biotin-based ester group;
- R′ and R″ denoting a hydrogen atom, a linear saturated C1-C6 or unsaturated C2-C6, or branched saturated or unsaturated C3-C6 hydrocarbon-based radical, optionally substituted with at least one group chosen from —OZ, —NZZ′ and —COOZ, Z and Z′ denoting, independently of each other, a hydrogen atom or a linear saturated C1-C6 or unsaturated C2-C6, or branched saturated or unsaturated C3-C6 hydrocarbon-based radical;
- and
- the salts, optical isomers and solvates thereof.
A device comprising a combination of at least one monosaccharide chosen from mannose and rhamnose and at least one additional compound chosen from adenosine and adenosine analogues, the device being capable of delivering the combination by intraepidermal and/or intradermal and/or subcutaneous injection.
Dependencies are inferred from the claim text.